Pharmaron Beijing Co (HKSE:03759) LT-Debt-to-Total-Asset : 0.20 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pharmaron Beijing Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.20.

Pharmaron Beijing Co's long-term debt to total assets ratio declined from Dec. 2023 (0.33) to Dec. 2024 (0.20). It may suggest that Pharmaron Beijing Co is progressively becoming less dependent on debt to grow their business.

Pharmaron Beijing Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Pharmaron Beijing Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co LT-Debt-to-Total-Asset Chart

Pharmaron Beijing Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.26

0.25

0.33

0.20

Pharmaron Beijing Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.33	0.29	0.21	0.20	0.20

Pharmaron Beijing Co LT-Debt-to-Total-Asset Calculation

Pharmaron Beijing Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	5102.058	/	25546.614
	=	0.20

Pharmaron Beijing Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	5102.058	/	25546.614
	=	0.20

Pharmaron Beijing Co (HKSE:03759) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pharmaron Beijing Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

300759:China

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.

Executives

Hsbc Holdings Plc	2106 Person having a security interest in shares
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Matthews International Capital Management, Llc	2102 Investment manager
First H Share Award And Scheme Of Pharmaron Beijing Co., Ltd.	2301 Trustee
Kastle Limited	2301 Trustee
Jian Xin Bei Jing Tou Zi Ji Jin Guan Li You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you
Jian Xin Xin Tuo You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you

Pharmaron Beijing Co Headlines

No Headlines